Low-dose radiation therapy looks effective in hard-to-treat MCLAugust 7, 2019Lymphoma & Plasma Cell Disorders
Researchers combine genetic and clinical factors in new VTE risk scoreJuly 31, 2019Lymphoma & Plasma Cell Disorders
BRCA2 mutations linked to childhood NHLJuly 25, 2019Patient & Survivor CarePediatricsPreventive CareLymphoma & Plasma Cell Disorders
Lymphoma risk prompts FDA recall of Allergan’s textured breast implantsJuly 24, 2019Lymphoma & Plasma Cell Disorders
BTK mutations linked to CLL progression on ibrutinibJuly 24, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
FDA approves rituximab biosimilar for cancer, autoimmune disordersJuly 23, 2019Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Chemo-free combo gets high response rate in relapsed or refractory DLBCLJuly 23, 2019DLBCLLymphoma & Plasma Cell Disorders
CAR T-cell therapy less effective in transformed follicular lymphomaJuly 22, 2019Follicular LymphomaLymphoma & Plasma Cell DisordersDLBCL
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCLJuly 18, 2019DLBCLLymphoma & Plasma Cell Disorders
On second thought, lenalidomide does improve DLBCL outcomesJuly 15, 2019DLBCLLymphoma & Plasma Cell Disorders
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Lymphoma & Plasma Cell Disorders
CNS-directed therapy appears more effective for synDLBCLJuly 9, 2019Lymphoma & Plasma Cell DisordersDLBCL
Daratumumab wins new indication for newly diagnosed myeloma patientsJune 28, 2019Lymphoma & Plasma Cell Disorders
